Anti-NMDA receptor encephalitis

Autoimmune diseases of the central nervous system (CNS) are one of the most socially and economically significant problems of neurology. Despite the identification of new nosological forms of autoimmune encephalitis, the creation of diagnostic panels for the verification of autoantibodies in biological fluids, and the use of highly effective pathogenetic therapy, the number of diagnostic errors remains high, which poses a threat to the patient’s life and a high risk of developing severe complications. Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis) is autoimmune encephalitis caused by the presence of antibodies (Ab) to the NR1 subunit of NMDA-receptors (NMDAR) characterized by the development of severe mental and neurological deficits in a previously healthy person. This article summarizes the recent literature on anti-NMDAR encephalitis. The literature search was carried out using the Scopus, Web of Science, Pubmed, CyberLeninka databases. The review presents the facts of the history of the study of the disease, epidemiological data, modern ideas about the pathogenetic mechanisms of the development of the disease, the spectrum of clinical manifestations and various forms of the course of the disease. The diagnostic criteria and research methods used to confirm the diagnosis are described, approaches to the treatment of anti-NMDAR encephalitis are outlined.

Anti-NMDAR encephalitis is clinically manifested by a combination of mental disorders, epileptic seizures, speech and extrapyramidal disorders, and disturbances in the rhythm of sleep and wakefulness. The disease occurs at any age. The development of the disease can be associated with such immunological triggers as oncological process and herpetic encephalitis, or be idiopathic in nature. There are features of the course of the clinical picture depending on the age of the patient, paraneoplastic or postherpetic aetiology of the disease. The diagnostic algorithm, along with neuroimaging, determination of specific antibodies, electroencephalography, should also include the search for an oncological process. The recovery of patients can take from several months to years. In some cases, persistent neurological deficits develop. Predictors of a favourable outcome include early initiation and use of combination therapy, detection and removal of neoplasms, a low titer of anti-NMDAR antibodies, and age of patients over 12 years of age. In up to 25% of cases, a relapsing course of the disease is possible, and therefore requires long-term monitoring of these patients.

1. Vitaliani R., Mason W., Ances B., Zwerdling T., Jiang Z., Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann. Neurol. 2005; 58(4): 594–604. https://doi.org/10.1002/ana.20614

2. Titulaer M.J., McCracken L., Gabilondo I., Armangué T., Glaser C., Iizuka T., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013; 12(2): 157–65. https://doi.org/10.1016/s1474-4422(12)70310-1

3. Fominykh V.V. Analysis of inflammatory and neurodegenerative processes in patients with autoimmune diseases of the central nervous system: Diss. Moscow; 2019. (in Russian)

4. Surovtseva A.V., Skripchenko N.V., Ivanova G.P., Pul’man N.F., Konev A.I. Anti-NMDA receptor encephalitis. Rossiyskiy vestnik perinatologii i pediatrii. 2014; 59(6): 103–5. (in Russian)

5. Bogadel’nikov I.V., Bobrysheva A.V., Vyal’tseva Yu.V., Chernyaeva E.S. Encephalitis, caused by NMDA-receptors antibodies of neurons. Zdorov’e rebenka. 2013; (3): 128–30. (in Russian)

6. Yang S., Yang L., Liao H., Chen M., Feng M., Liu S., et al. Clinical characteristics and prognostic factors of children with anti-N-me­thyl-D-aspartate receptor encephalitis. Front. Pediatr. 2021; 9: 605042. https://doi.org/10.3389/fped.2021.605042

7. Titulaer M.J., McCracken L., Gabilondo I., Iizuka T., Kawachi I., Bataller L., et al. Late-onset anti-NMDA receptor encephalitis. Neurology. 2013; 81(12): 1058–63. https://doi.org/10.1212/wnl.0b013e3182a4a49c

8. Haberny K.A., Paule M.G., Scallet A.C., Sistare F.D., Lester D.S., Hanig J.P., et al. Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicol. Sci. 2002; 68(1): 9–17. https://doi.org/10.1093/toxsci/68.1.9

9. Florance-Ryan N., Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr. Opin. Pediatr. 2010; 22(6): 739–44. https://doi.org/10.1097/mop.0b013e3283402d2f

10. Gable M., Glaser C. Anti-n-methyl-d-aspartate receptor encephalitis appearing as a new-onset psychosis: disease course in children and adolescents within the California encephalitis project. Pediatr. Neurol. 2017; 72: 25–30. https://doi.org/10.1016/j.pediatrneurol.2017.01.023

11. Luca N., Daengsuwan T., Dalmau J., Jones K., deVeber G., Kobayashi J., et al. Anti-n-methyl-d-aspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. Arthritis Rheum. 2011; 63(8): 2516–22. https://doi.org/10.1002/art.30437

12. Dalmau J. NMDA receptor encephalitis and other antibody-media­ted disorders of the synapse: The 2016 cotzias lecture. Neurology. 2016; 87(23): 2471–82. https://doi.org/10.1212/wnl.0000000000003414

13. Gomes F.M., Lapresa A.V., García S.M.H., Hernández H.L., Doya­gue S.M.J. Successful treatment of anti-NMDA receptor encephalitis with early teratoma removal and plasmapheresis: A case report. Medicine (Baltimore). 2018; 97(31): e11325. https://doi.org/10.1097/md.0000000000011325

14. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008; 7(12): 1091–8. https://doi.org/10.1016/s1474-4422(08)70224-2

15. Uchino A., Iizuka T., Urano Y., Arai M., Hara A., Hamada J., et al. Pseudo-piano playing motions and nocturnal hypoventilation in anti-NMDA receptor encephalitis: response to prompt tumor removal and immunotherapy. Intern. Med. 2011; 50(6): 627–30. https://doi.org/10.2169/internalmedicine.50.4764

16. Lancaster E., Martinez-Hernandez E., Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011; 77(2): 179–89. https://doi.org/10.1212/wnl.0b013e318224afde

17. Zandi M.S., Irani S.R., Follows G., Moody A.M., Molyneux P., Vincent A. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. Neurology. 2009; 73(23): 2039–40. https://doi.org/10.1212/wnl.0b013e3181c55e9b

18. Sanmaneechai O., Song J.L., Nevadunsky N., Moshé S.L., Overby P.J. Anti-N-methyl-D-aspartate encephalitis with ovarian cystadenofibroma. Pediatr. Neurol. 2013; 48(3): 232–5. https://doi.org/10.1016/j.pediatrneurol.2012.10.013

19. Lebas A., Husson B., Didelot A., Honnorat J., Tardieu M. Expanding spectrum of encephalitis with NMDA receptor antibodies in young children. J. Child. Neurol. 2010; 25(6): 742–5. https://doi.org/10.1177/0883073809343319

20. Armangue T., Leypoldt F., Málaga I., Raspall-Chaure M., Marti I., Nichter C., et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann. Neurol. 2014; 75(2): 317–23. https://doi.org/10.1002/ana.24083

21. Armangue T., Moris G., Cantarín-Extremera V., Conde C.E., Rostasy K., Erro M.E., et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology. 2015; 85(20): 1736–43. https://doi.org/10.1212/wnl.0000000000002125

22. Armangue T., Spatola M., Vlagea A., Mattozzi S., Cárceles-Cordon M., Martinez-Heras E., et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018; 17(9): 760–72. https://doi.org/10.1016/s1474-4422(18)30244-8

23. Prüss H., Finke C., Höltje M., Hofmann J., Klingbeil C., Probst C., et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann. Neurol. 2012; 72(6): 902–11. https://doi.org/10.1002/ana.23689

24. Hacohen Y., Deiva K., Pettingill P., Waters P., Siddiqui A., Chretien P., et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov. Disord. 2014; 29(1): 90–6. https://doi.org/10.1002/mds.25626

25. Sutcu M., Akturk H., Somer A., Tatli B., Torun S.H., Yıldız E.P., et al. Role of autoantibodies to n-methyl-d-aspartate (NMDA) receptor in relapsing herpes simplex encephalitis: a retrospective, one-center experience. J. Child. Neurol. 2016; 31(3): 345–50. https://doi.org/10.1177/0883073815595079

26. Titulaer M.J., Leypoldt F., Dalmau J. Antibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis. Mov. Disord. 2014; 29(1): 3–6. https://doi.org/10.1002/mds.25716

27. Burr T., Barton C., Doll E., Lakhotia A., Sweeney M. N-methyl-D-aspartate receptor encephalitis associated with COVID-19 infection in a toddler. Pediatr. Neurol. 2021; 114: 75–6. https://doi.org/10.1016/j.pediatrneurol.2020.10.002

28. Monti G., Giovannini G., Marudi A., Bedin R., Melegari A., Simone A.M., et al. Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19. Seizure. 2020; 81: 18–20. https://doi.org/10.1016/j.seizure.2020.07.006

29. Panariello A., Bassetti R., Radice A., Rossotti R., Puoti M., Corradin M., et al. Anti-NMDA receptor encephalitis in a psychiatric COVID-19 patient: A case report. Brain Behav. Immun. 2020; 87: 179–81. https://doi.org/10.1016/j.bbi.2020.05.054

30. Ursitti F., Roberto D., Papetti L., Moavero R., Ferilli M.A.N., Fusco L., et al. Diagnosis of pediatric anti-NMDAR encephalitis at the onset: A clinical challenge. Eur. J. Paediatr Neurol. 2021; 30: 9–16. https://doi.org/10.1016/j.ejpn.2020.12.004

31. Dalmau J., Tüzün E., Wu H., Masjuan J., Rossi J.E., Voloschin A., et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 2007; 61(1): 25–36. https://doi.org/10.1002/ana.21050

32. Murashko A.A., Kir’yanova E.M., Sal’nikova L.I., Spektor V.A. Clinical and epidemiological features of psychotic spectrum disorders associated with NMDA receptor antibodies: study. Sotsial’naya i klinicheskaya psikhiatriya. 2020; 30(3): 37–42. (in Russian)

33. Vasenina E.E., Levin O.S., Gan’kina O.A., Chimagomedova A.Sh., Levikov D.I. Autoimmune anti-nmda-r encephalitis. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2017; 117(2): 110–6. https://doi.org/10.17116/jnevro201711721110-116 (in Russian)

34. Hammer C., Stepniak B., Schneider A., Papiol S., Tantra M., Begemann M., et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol. Psychiatry. 2014; 19(10): 1143–9. https://doi.org/10.1038/mp.2013.110

35. Lee K.W., Liou L.M., Wu M.N. Fulminant course in a patient with anti-N-methyl-D-aspartate receptor encephalitis with bilateral ovarian teratomas: A case report and literature review. Medicine (Baltimore). 2018; 97(15): e0339. https://doi.org/10.1097/md.0000000000010339

36. Ariño H., Muñoz-Lopetegi A., Martinez-Hernandez E., Armangue T., Rosa-Justicia M., Escudero D., et al. Sleep disorders in anti-NMDAR encephalitis. Neurology. 2020; 95(6): e671–84. https://doi.org/10.1212/wnl.0000000000009987

37. Cheng H., Yang F., Zhang J., Xu L., Jia L., Zhao D., et al. Case report: anti-NMDA receptor encephalitis with bilateral hearing loss as the initial symptom. Front. Neurol. 2021; 12. https://doi.org/10.3389/fneur.2021.648911

38. Wright S., Hacohen Y., Jacobson L., Agrawal S., Gupta R., Philip S., et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Arch. Dis. Child. 2015; 100(6): 521–6. https://doi.org/10.1136/archdischild-2014-306795

39. Qu X.P., Vidaurre J., Peng X.L., Jiang L., Zhong M., Hu Y. Seizure characteristics, outcome, and risk of epilepsy in pediatric anti-N-methyl-D-aspartate receptor encephalitis. Pediatr. Neurol. 2020; 105: 35–40. https://doi.org/10.1016/j.pediatrneurol.2019.11.011

40. Sarkis R.A., Coffey M.J., Cooper J.J., Hassan I., Lennox B. Anti-N-methyl-D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations: a report of the American neuropsychiatric association committee on research. J. Neuropsychiatry Clin. Neurosci. 2019; 31(2): 137–42. https://doi.org/10.1176/appi.neuropsych.18010005

41. Graus F., Titulaer M.J., Balu R., Benseler S., Bien C.G., Cellucci T., et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15(4): 391–404. https://doi.org/10.1016/s1474-4422(15)00401-9

42. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011; 10(1): 63–74. https://doi.org/10.1016/s1474-4422(10)70253-2

43. Schou M.B., Sæther S.G., Drange O.K., Brenner E., Crespi J., Eikenes L., et al. A prospective three-year follow-up study on the clinical significance of anti-neuronal antibodies in acute psychiatric disorders. Sci. Rep. 2019; 10(1): 35. https://doi.org/10.1038/s41598-019-56934-6

44. Leypoldt F., Buchert R., Kleiter I., Marienhagen J., Gelderblom M., Magnus T., et al. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J. Neurol. Neurosurg. Psychiatr. 2012; 83(7): 681–6. https://doi.org/10.1136/jnnp-2011-301969

45. Miao A., Shi Y., Xiang J., Wang X., Ge J., Chen Q., et al. Using EEG and MEG to characterize extreme delta brush in a patient with anti-NMDA receptor encephalitis. BMC Neurol. 2021; 21(1): 134. https://doi.org/10.1186/s12883-021-02157-0

46. Moise A.M., Karakis I., Herlopian A., Dhakar M., Hirsch L.J., Cotsonis G., et al. Continuous EEG findings in autoimmune encephalitis. J. Clin. Neurophysiol. 2021; 38(2): 124–9. https://doi.org/10.1097/wnp.0000000000000654

47. Jeannin-Mayer S., André-Obadia N., Rosenberg S., Boutet C., Honnorat J., Antoine J.C., et al. EEG analysis in anti-NMDA receptor encephalitis: description of typical patterns. Clin. Neurophysiol. 2019; 130(2): 289–96. https://doi.org/10.1016/j.clinph.2018.10.017

48. Söylemez E., Güveli B.T., Atakli D., Yatmazoğlu M., Atay T., Dayan C. Extreme delta brush eeg pattern in a case with anti-NMDA receptor encephalitis. Ideggyogy Sz. 2015; 68(9-10): 357–60. https://doi.org/10.18071/isz.68.0357

49. Veciana M., Becerra J.L., Fossas P., Muriana D., Sansa G., Santamarina E., et al. EEG extreme delta brush: An ictal pattern in patients with anti-NMDA receptor encephalitis. Epilepsy Behav. 2015; 49: 280–5. https://doi.org/10.1016/j.yebeh.2015.04.032

50. Zuliani L., Graus F., Giometto B., Bien C., Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J. Neurol. Neurosurg. Psychiatr. 2012; 83(6): 638–45. https://doi.org/10.1136/jnnp-2011-301237

51. Granerod J., Ambrose H.E., Davies N.W., Clewley J.P., Walsh A.L., Morgan D., et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect. Dis. 2010; 10(12): 835–44. https://doi.org/10.1016/s1473-3099(10)70222-x

52. Peery H.E., Day G.S., Doja A., Xia C., Fritzler M.J., Foster W.G. Anti-NMDA receptor encephalitis in children: the disorder, its diagnosis, and treatment. Handb. Clin. Neurol. 2013; 112: 1229–33. https://doi.org/10.1016/b978-0-444-52910-7.00045-3

53. Zekeridou A., Karantoni E., Viaccoz A., Ducray F., Gitiaux C., Villega F., et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J. Neurol. 2015; 262(8): 1859–66. https://doi.org/10.1007/s00415-015-7781-9

54. Wu P.M., Teng C.K., Chou Y.Y., Tu Y.F. Precocious puberty as a consequence of anti-NMDA receptor encephalitis in children. Pediatr. Neonatol. 2021; 62(4): 361–8. https://doi.org/10.1016/j.pedneo.2021.03.004

55. Badalyan O.L., Burd S.G., Lebedeva A.V., Avakyan G.G., Oleynikova O.M., Savenkov A.A. Paradigms of modern epileptology. Consilium Medicum. 2021; 23(2): 154–60. https://doi.org/10.26442/20751753.2021.2.200738 (in Russian)